Professor Andreas Bender

Currently also: Chief Informatics and Technology Officer (CITO) at Pangea Botanica, London/UK and Berlin/Germany

Previous positions:

Director Digital Chemistry at NUVISAN Berlin

Associate Director Computational ADME and Safety (Clinical Pharmacology & Safety Sciences/Data Science and Artificial Intelligence - CPSS/DSAI) at AstraZeneca Cambridge

Co-founder of Healx Ltd.

Co-founder of PharmEnable Ltd.

Personal Website

Committed to developing new life science data analysis methods (AI/ML/data science) and their application, primarily related to chemical biology, drug discovery and in silico toxicology
Expertise comprises data ranging from chemical structure and gene expression data to phenotypic readouts and preclinical information, applied to both efficacy- and safety/tox-related questions
Collaborating with academic research groups, as well as pharmaceutical, chemical, and consumer goods companies (Eli Lilly, AstraZeneca, GSK, BASF, Johnson&Johnson/Janssen, Unilever, ...)
Co-founder/founding CTO and current SAB member of Healx Ltd. (data-driven drug repurposing for rare diseases, and beyond); co-founder of PharmEnable Ltd.; SAB member of Lhasa Ltd. (toxicology and metabolism prediction) and Cresset Ltd.
Coordinator of the Computational & In Silico Toxicology Specialty Section of the British Toxicology Society (BTS)
Steering Committee Member of the Cambridge Alliance on Medicines Safety (CAMS)
Currently leading a group of ca. 15 PhD students, postdocs, project students and visitors at the Centre for Molecular Informatics at the University of Cambridge, https://www-cmi.ch.cam.ac.uk/centre-molecular-informatics

Publications

Applications of proteochemometrics - from species extrapolation to cell line sensitivity modelling

I Cortes-Ciriano, GJP van Westen, DS Murrell, EB Lenselink, A Bender, TE Malliavin

BMC Bioinformatics

(2015)

(doi: 10.1186/1471-2105-16-s3-a4)

Microwave-assisted synthesis, characterization and cytotoxic studies of novel estrogen receptor α ligands towards human breast cancer cells.

H Bharathkumar, CD Mohan, H Ananda, JE Fuchs, F Li, S Rangappa, M Surender, KC Bulusu, KS Girish, G Sethi, A Bender, Basappa, KS Rangappa

Bioorg Med Chem Lett

(2015)

1804

(doi: 10.1016/j.bmcl.2015.01.030)

Analyzing multitarget activity landscapes using protein-ligand interaction fingerprints: interaction cliffs.

O Méndez-Lucio, AJ Kooistra, C de Graaf, A Bender, JL Medina-Franco

J Chem Inf Model

(2015)

251

(doi: 10.1021/ci500721x)

Prediction of the potency of mammalian cyclooxygenase inhibitors with ensemble proteochemometric modeling

I Cortes-Ciriano, DS Murrell, GJ van Westen, A Bender, TE Malliavin

Journal of cheminformatics

(2015)

(doi: 10.1186/s13321-014-0049-z)

Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project

B Verbist, G Klambauer, L Vervoort, W Talloen, QSTAR Consortium, Z Shkedy, O Thas, A Bender, HWH Göhlmann, S Hochreiter

Drug Discov Today

(2015)

505

(doi: 10.1016/j.drudis.2014.12.014)

A One Pot Synthesis of Novel Bioactive Tri-Substitute-Condensed-Imidazopyridines that Targets Snake Venom Phospholipase A₂

NC Anilkumar, MS Sundaram, CD Mohan, S Rangappa, KC Bulusu, JE Fuchs, KS Girish, A Bender, Basappa, KS Rangappa

PloS one

(2015)

e0131896

(doi: 10.1371/journal.pone.0131896)

Synthesis, characterization and in vitro evaluation of novel enantiomerically-pure sulphonamide antimalarials

S Anusha, A Sinha, CP Babu Rajeev, TTT Chu, J Mathai, H Ximei, JE Fuchs, N Shivananju, A Bender, PR Preiser, KS Rangappa, Basappa, R Chandramohanadas

Org Biomol Chem

(2015)

10681

(doi: 10.1039/c5ob01479d)

Which kinase to hit in NCI-60? From a selectivity problem to a multitarget solution

OM Lucio, AC Ravindranath, Q Ul Ain, K Birchall, C Mpamhanga, S Knapp, A Bender

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY

(2015)

250

Computational methods for small molecule selection in stem cell differentiation

A Bender, YK Motamedi, M Peymani, MH Nasr-Esfahani

European Pharmaceutical Review

(2015)

Identification of the first surrogate agonists for the G protein-coupled receptor GPR132

MA Shehata, H Belcik Christensen, V Isberg, D Sejer Pedersen, A Bender, H Bräuner-Osborne, DE Gloriam

Rsc Advances

(2015)

48551

(doi: 10.1039/c5ra04804d)

Professor Andreas Bender

Publications

Research Interest Groups

Telephone number

Email address

About the Department

Departmental Services

Bender Group

Study at Cambridge

About the University

Research at Cambridge